{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:04:38Z","timestamp":1794693878137,"version":"4.9.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["2024-186"],"award-info":[{"award-number":["2024-186"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with estrogen receptor-positive (ER\n                    <jats:sup>+<\/jats:sup>\n                    ), HER2-negative, early breast cancer (BC) have low pathologic complete response (pCR) rates following neoadjuvant chemotherapy. Immune checkpoint inhibitors (ICIs) provide limited benefit in programmed death-ligand 1 (PD-L1)-negative tumors, characterized by an immune-cold tumor microenvironment. Here we hypothesized that immune-modulating stereotactic body radiation therapy (iSBRT; 3\u2009\u00d7\u20098\u2009Gy) could enhance response through tumor microenvironment reprogramming, and that CD73 blockade could further improve efficacy. We conducted a phase 2, randomized, multicenter trial (Neo-CheckRay) in 147 female patients with high-risk, ER\n                    <jats:sup>+<\/jats:sup>\n                    HER2\n                    <jats:sup>\u2212<\/jats:sup>\n                    early BC. Patients received neoadjuvant chemotherapy plus iSBRT alone (No_ICI), with anti-PD-L1 durvalumab (Single_ICI) or with durvalumab plus anti-CD73 oleclumab (Double_ICI). In the intention-to-treat population, the primary endpoint, residual cancer burden 0\/1 rate, was 35.4% with No_ICI, 45.1% with Single_ICI and 47.9% with Double_ICI, without statistically significant differences. pCR rates were 16.7%, 29.4% and 33.3%, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.059). In the per-protocol population (MammaPrint High Risk,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009131), pCR rates were 16.3%, 32.6% and 35.6%, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.040). Among PD-L1-negative tumors (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200991), pCR rates were 3.4%, 28.1% and 30.0%, respectively. No new safety signals were observed. Baseline transcriptomic analysis showed low immune signature expression in PD-L1-negative tumors. Paired baseline and on-treatment biopsies obtained 1\u2009week after iSBRT demonstrated tumor microenvironment reprogramming toward an inflamed phenotype in the iSBRT\u2009+\u2009anti-PD-L1 arms. These findings suggest that iSBRT\u2009+\u2009anti-PD-L1 may convert immune-cold ER\n                    <jats:sup>+<\/jats:sup>\n                    HER2\n                    <jats:sup>\u2212<\/jats:sup>\n                    BC into more inflamed tumors and improve response, particularly in PD-L1-negative disease. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03875573\" ext-link-type=\"uri\">NCT03875573<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04453-z","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:02:22Z","timestamp":1782378142000},"page":"2461-2472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2\u2212 breast cancer: a randomized phase 2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5989-7017","authenticated-orcid":false,"given":"Alex","family":"De Caluw\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desmoulins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2475-1821","authenticated-orcid":false,"given":"Kim","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Remouchamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adinda","family":"Baten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonore","family":"Longton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Peignaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Joaquin Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9038-5271","authenticated-orcid":false,"given":"David","family":"Venet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Arecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-7511","authenticated-orcid":false,"given":"Elisa","family":"Agostinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7864-3637","authenticated-orcid":false,"given":"Guilherme","family":"Nader-Marta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00eb","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dhont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1657-5250","authenticated-orcid":false,"given":"Paulus","family":"Kristanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Catteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Larsimont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1110-3801","authenticated-orcid":false,"given":"Roberto","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Poortmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Stagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5745-9977","authenticated-orcid":false,"given":"Christos","family":"Sotiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-3748","authenticated-orcid":false,"given":"Michail","family":"Ignatiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1574-5545","authenticated-orcid":false,"given":"Emanuela","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-0819","authenticated-orcid":false,"given":"Laurence","family":"Buisseret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"4453_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"4453_CR2","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1200\/JCO.2013.54.1870","volume":"32","author":"F Ades","year":"2014","unstructured":"Ades, F. et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J. Clin. Oncol. 32, 2794\u20132803 (2014).","journal-title":"J. Clin. Oncol."},{"key":"4453_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso, F. et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. New Engl. J. Med. 375, 717\u2013729 (2016).","journal-title":"New Engl. J. Med."},{"key":"4453_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMra0801289","volume":"360","author":"C Sotiriou","year":"2009","unstructured":"Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. New Engl. J. Med. 360, 790\u2013800 (2009).","journal-title":"New Engl. J. Med."},{"key":"4453_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"46","author":"S Loibl","year":"2024","unstructured":"Loibl, S. et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 5 behalf of the ESMO Guidelines Committee. Ann. Oncol. 46, 159\u2013182 (2024).","journal-title":"Ann. Oncol."},{"key":"4453_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164\u2013172 (2014).","journal-title":"Lancet"},{"key":"4453_CR7","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans, W. F. et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J. Clin. Oncol. 35, 1049\u20131060 (2017).","journal-title":"J. Clin. Oncol."},{"key":"4453_CR8","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrclinonc.2013.124","volume":"10","author":"M Ignatiadis","year":"2013","unstructured":"Ignatiadis, M. & Sotiriou, C. Luminal breast cancer: from biology to treatment. Nat. Rev. Clin. Oncol. 10, 494\u2013506 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4453_CR9","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid, P. et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. New Engl. J. Med. 391, 1981\u20131991 (2024).","journal-title":"New Engl. J. Med."},{"key":"4453_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. New Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"New Engl. J. Med."},{"key":"4453_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso, F. et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2212 breast cancer: a randomized phase 3 trial. Nat. Med. 31, 442\u2013448 (2025).","journal-title":"Nat. Med."},{"key":"4453_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi, S. et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat. Med. 31, 433\u2013441 (2025).","journal-title":"Nat. Med."},{"key":"4453_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/CCO.0000000000001183","volume":"37","author":"L Arecco","year":"2025","unstructured":"Arecco, L. et al. Immunotherapy in the neoadjuvant treatment of hormone receptor-positive\/HER2-negative early breast cancer: novel approaches and future perspectives. Curr. Opin. Oncol. 37, 552\u2013561 (2025).","journal-title":"Curr. Opin. Oncol."},{"key":"4453_CR14","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","volume":"2","author":"SE Stanton","year":"2016","unstructured":"Stanton, S. E., Adams, S. & Disis, M. L. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2, 1354\u20131360 (2016).","journal-title":"JAMA Oncol."},{"key":"4453_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/2159-8290.CD-22-0475","volume":"13","author":"SS Onkar","year":"2023","unstructured":"Onkar, S. S. et al. The great immune escape: understanding the divergent immune response in breast cancer subtypes. Cancer Discov. 13, 23\u201340 (2023).","journal-title":"Cancer Discov."},{"key":"4453_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20138-8","volume":"11","author":"C G\u00f3mez-Aleza","year":"2020","unstructured":"G\u00f3mez-Aleza, C. et al. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Nat. Commun. 11, 6335 (2020).","journal-title":"Nat. Commun."},{"key":"4453_CR17","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"S Demaria","year":"2015","unstructured":"Demaria, S., Golden, E. B. & Formenti, S. C. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 1, 1325\u20131332 (2015).","journal-title":"JAMA Oncol."},{"key":"4453_CR18","doi-asserted-by":"publisher","first-page":"2608436","DOI":"10.1080\/2162402X.2025.2608436","volume":"31","author":"MM Cogels","year":"2026","unstructured":"Cogels, M. M., de Caluw\u00e9, A., Buisseret, L. & Penninckx, S. Unlocking the therapeutic potential of immuno-radiotherapy: insights from preclinical and clinical research. Oncoimmunology 31, 2608436 (2026).","journal-title":"Oncoimmunology"},{"key":"4453_CR19","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","volume":"25","author":"C Lynch","year":"2024","unstructured":"Lynch, C., Pitroda, S. P. & Weichselbaum, R. R. Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 25, e352\u2013e362 (2024).","journal-title":"Lancet Oncol."},{"key":"4453_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110836","volume":"206","author":"A De Caluw\u00e9","year":"2025","unstructured":"De Caluw\u00e9, A. et al. Adapting radiation therapy to immunotherapy: delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial. Radiother. Oncol. 206, 110836 (2025).","journal-title":"Radiother. Oncol."},{"key":"4453_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49873-y","volume":"15","author":"I Telarovic","year":"2024","unstructured":"Telarovic, I. et al. Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease. Nat. Commun. 15, 5500 (2024).","journal-title":"Nat. Commun."},{"key":"4453_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1158\/2326-6066.CIR-19-0449","volume":"8","author":"E Wennerberg","year":"2020","unstructured":"Wennerberg, E. et al. CD73 blockade promotes dendritic cell infiltration of irradiated tumors and tumor rejection. Cancer Immunol. Res. 8, 465\u2013478 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"4453_CR23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard, B., Allard, D., Buisseret, L. & Stagg, J. The adenosine pathway in immuno-oncology. Nat. Rev. Clin. Oncol. 17, 611\u2013629 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4453_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","volume":"22","author":"C Xia","year":"2023","unstructured":"Xia, C., Yin, S., To, K. K. W. & Fu, L. CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol. Cancer 22, 44 (2023).","journal-title":"Mol. Cancer"},{"key":"4453_CR25","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/annonc\/mdx730","volume":"29","author":"L Buisseret","year":"2018","unstructured":"Buisseret, L. et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. Ann. Oncol. 29, 1056\u20131062 (2018).","journal-title":"Ann. Oncol."},{"key":"4453_CR26","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1186\/s12885-021-08601-1","volume":"21","author":"A De Caluw\u00e9","year":"2021","unstructured":"De Caluw\u00e9, A. et al. Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial. BMC Cancer 21, 899 (2021).","journal-title":"BMC Cancer"},{"key":"4453_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol. Cancer 22, 194 (2023).","journal-title":"Mol. Cancer"},{"key":"4453_CR28","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","volume":"24","author":"AE Marciscano","year":"2018","unstructured":"Marciscano, A. E. et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin. Cancer Res. 24, 5058\u20135071 (2018).","journal-title":"Clin. Cancer Res."},{"key":"4453_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34676-w","volume":"13","author":"LB Darragh","year":"2022","unstructured":"Darragh, L. B. et al. Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat. Commun. 13, 7015 (2022).","journal-title":"Nat. Commun."},{"key":"4453_CR30","doi-asserted-by":"publisher","first-page":"eabg0117","DOI":"10.1126\/sciimmunol.abg0117","volume":"6","author":"J Wei","year":"2021","unstructured":"Wei, J. et al. Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Sci. Immunol. 6, eabg0117 (2021).","journal-title":"Sci. Immunol."},{"key":"4453_CR31","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi, S. J. et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458\u20135468 (2014).","journal-title":"Cancer Res."},{"key":"4453_CR32","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1200\/JCO.24.00003","volume":"42","author":"AY Ho","year":"2024","unstructured":"Ho, A. Y. et al. PEARL: a phase Ib\/II biomarker study of adding radiation therapy to pembrolizumab before neoadjuvant chemotherapy in human epidermal growth factor receptor 2-negative breast cancer. J. Clin. Oncol. 42, 4282\u20134293 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4453_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","volume":"42","author":"SL Shiao","year":"2024","unstructured":"Shiao, S. L. et al. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell 42, 70\u201384 (2024).","journal-title":"Cancer Cell"},{"key":"4453_CR34","doi-asserted-by":"publisher","first-page":"e002038","DOI":"10.1136\/jitc-2020-002038","volume":"9","author":"S Demaria","year":"2021","unstructured":"Demaria, S. et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?. J. Immunother. Cancer 9, e002038 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"4453_CR35","doi-asserted-by":"publisher","first-page":"OT3-15-01","DOI":"10.1158\/1538-7445.SABCS22-OT3-15-01","volume":"83","author":"JJ Connolly","year":"2023","unstructured":"Connolly, J. J. et al. Abstract OT3-15-01: TBCRC-053: P-RAD: a randomized study of preoperative chemotherapy, pembrolizumab and no, low or high dose radiation in node-positive, HER2-negative breast cancer. Cancer Res. 83, OT3-15-01 (2023).","journal-title":"Cancer Res."},{"key":"4453_CR36","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s43018-025-01018-w","volume":"6","author":"J Huang","year":"2025","unstructured":"Huang, J. et al. Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer. Nat. Cancer 6, 1676\u20131692 (2025).","journal-title":"Nat. Cancer"},{"key":"4453_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42744-y","volume":"14","author":"L Buisseret","year":"2023","unstructured":"Buisseret, L. et al. Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I\/II trial. Nat. Commun. 14, 7018 (2023).","journal-title":"Nat. Commun."},{"key":"4453_CR38","doi-asserted-by":"crossref","unstructured":"Herbst, R. S. et al. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non\u2013small-cell lung cancer. J. Clin. Oncol. 40, 3383\u20133393 (2022).","DOI":"10.1200\/JCO.22.00227"},{"key":"4453_CR39","doi-asserted-by":"publisher","first-page":"e008864","DOI":"10.1136\/jitc-2024-008864","volume":"12","author":"Y Choi","year":"2024","unstructured":"Choi, Y. et al. Novel insights into paclitaxel\u2019s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment. J. Immunother. Cancer 12, e008864 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"4453_CR40","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1158\/0008-5472.CAN-17-3480","volume":"78","author":"CW Wanderley","year":"2018","unstructured":"Wanderley, C. W. et al. Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Cancer Res. 78, 5891\u20135900 (2018).","journal-title":"Cancer Res."},{"key":"4453_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"4453_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54145-w","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nat. Commun. 15, 10232 (2024).","journal-title":"Nat. Commun."},{"key":"4453_CR43","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"4453_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn8390","volume":"7","author":"YJ Lee","year":"2026","unstructured":"Lee, Y. J. et al. CD39+ tissue-resident memory CD8+ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer. Sci. Immunol. 7, eabn8390 (2026).","journal-title":"Sci. Immunol."},{"key":"4453_CR45","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/1078-0432.CCR-19-2183","volume":"26","author":"B Sidders","year":"2020","unstructured":"Sidders, B. et al. Adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response. Clin. Cancer Res. 26, 2176\u20132187 (2020).","journal-title":"Clin. Cancer Res."},{"key":"4453_CR46","doi-asserted-by":"crossref","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists guideline update. Arch. Pathol. Lab. Med. 144, 545\u2013563 (2020).","DOI":"10.5858\/arpa.2019-0904-SA"},{"key":"4453_CR47","unstructured":"Edge, S. et al. (eds) AJCC Cancer Staging Manual 7th edn (Springer, 2010)."},{"key":"4453_CR48","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649\u2013656 (1982).","journal-title":"Am. J. Clin. Oncol."},{"key":"4453_CR49","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans, W. F. et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 25, 4414\u20134422 (2007).","journal-title":"J. Clin. Oncol."},{"key":"4453_CR50","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 (National Cancer Institute, 2018)."},{"key":"4453_CR51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","volume":"93","author":"LM McShane","year":"2005","unstructured":"McShane, L. M. et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer 93, 387\u2013391 (2005).","journal-title":"Br. J. Cancer"},{"key":"4453_CR52","doi-asserted-by":"publisher","DOI":"10.1177\/15330338251407734","volume":"25","author":"T Yin","year":"2026","unstructured":"Yin, T. et al. Fully automated stain quantification framework for IHC whole slide images in breast cancer. Technol. Cancer Res. Treat. 25, 15330338251407734 (2026).","journal-title":"Technol. Cancer Res. Treat."},{"key":"4453_CR53","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","volume":"40","author":"DM Wolf","year":"2022","unstructured":"Wolf, D. M. et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies. Cancer Cell 40, 609\u2013623 (2022).","journal-title":"Cancer Cell"},{"key":"4453_CR54","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"4453_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"4453_CR56","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"4453_CR57","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.1","volume":"4","author":"C Soneson","year":"2015","unstructured":"Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4, 1521 (2015).","journal-title":"F1000Res"},{"key":"4453_CR58","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/nprot.2009.97","volume":"4","author":"S Durinck","year":"2009","unstructured":"Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R\/Bioconductor package biomaRt. Nat. Protoc. 4, 1184\u20131191 (2009).","journal-title":"Nat. Protoc."},{"key":"4453_CR59","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1093\/bioinformatics\/bti525","volume":"21","author":"S Durinck","year":"2005","unstructured":"Durinck, S. et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics 21, 3439\u20133440 (2005).","journal-title":"Bioinformatics"},{"key":"4453_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"4453_CR61","doi-asserted-by":"crossref","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).","DOI":"10.1186\/1471-2105-14-7"},{"key":"4453_CR62","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"4453_CR63","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Series B Stat. Methodol."},{"key":"4453_CR64","doi-asserted-by":"publisher","first-page":"e007279","DOI":"10.1136\/jitc-2023-007279","volume":"11","author":"A De Caluw\u00e9","year":"2023","unstructured":"De Caluw\u00e9, A. et al. First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial. J. Immunother. Cancer 11, e007279 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"4453_CR65","doi-asserted-by":"publisher","unstructured":"De Caluw\u00e9, A. et al. Source files and R code for Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+\/HER2\u2212 breast cancer: a randomised phase 2 trial. figshare https:\/\/doi.org\/10.6084\/m9.figshare.29489597 (2026).","DOI":"10.6084\/m9.figshare.29489597"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04453-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04453-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04453-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:02:11Z","timestamp":1784210531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04453-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4453"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04453-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7159624\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D.C.: Institutional, AstraZeneca. C.S.: Institutional: Astellas; Institutional: Cepheid; Institutional: Vertex; Institutional: Seattle Genetics; Institutional: Puma; Institutional: AMGEN; Institutional: Eisai; Travel: Roche; Travel: Gilead; Travel: Roche; Internal speaker: Genentech; Regional speaker: Pfizer; Consultant or advisory role (honoraria): Exact Sciences; Institutional: Merck & Co; Consultant or advisory role (honoraria): prIME Oncology. E.A.: Advisory board for AstraZeneca; Honoraria from: Eli Lilly, Sandoz, AstraZeneca, Bayer, Abscint. Research grant to institution from: Gilead. Travel grants from: Novartis, Roche, Eli Lilly, Daiichi Sankyo, AstraZeneca, Abscint, Menarini. E.R.: Institutional, BMS; Institutional: AstraZeneca; Institutional: Replimune. Research fundings: Fondation Amgen, Fondation BMS; travel grant from Roche, BMS, Merck. Research fundings: Amgen. A.G.: Financial Interests, Institutional, AstraZeneca; Financial Interests, Institutional: Daiichi. G.N.-M.: Speaker honoraria from AstraZeneca and Novartis. L.A.: Support for attending medical conferences from: AstraZeneca; Institutional: Gilead. L.B.: institutional research grant from AstraZeneca; speaker honoraria from BMS, Novartis; travel grant from Roche, GILEAD. Advisory Board: Iteos, Domain Therapeutics. M.I.: Consultant or advisory role (honoraria): Celgene, Novartis, Pfizer, Seattle Genetics, Tesaro. Research grants to institution: Roche, Menarini Silicon Biosystems, Janssen Diagnostics, Pfizer. No stock ownership. Travel grants: Pfizer, Amgen. M.P.: Board Member (Scientific Board): Oncolytics; Consultant (honoraria): AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Periphagen, Pfizer, Roche, Seattle Genetics. Research grants to institution: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genetech, Servier, Synthon. No stock ownership. R.S.: personal honoraria from Astra Zeneca (Advisory Board, Invited Speaker), Bristol Myers Squibb (BMS) (Advisory Board), Daiichi Sankyo (Advisory Board, Invited Speaker), Exact Science (Advisory Board), Roche (Advisory Board, and personal funding for the assessment of immune-markers in a research study in 2019); and institutional funding from BMS (trial research support), Puma Biotechnology. R.S. Non-financial advisory roles for Case 45, the government of Belgium, and EORTC (Member of the EORTC Board). P.H.P.: medical advisor for Affidea BV. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}